- Eli Lilly and Company. Product Information: Xigris®, Drotrecogen Alfa (Activated). Indianapolis: Eli Lilly and Company, 2001.
- Opal SM, Cross AS. Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 1999;13: 285–297.
- Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Krauss WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Chest 1992;101: 1644–1655.
- Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340: 207–214.
- Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112: 235–243.
- Linde-Zwirble WT, Angus DC, Carcillo J, Lidicker J, Clermont G, Pinsky MR. Age specific incidence and outcome of sepsis in the US. Crit Care Med 1999; 27 (1 Supp): 33A.
- Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29: 1303–1310.
- Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274: 968–974.
- Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344: 699–709.
- Fisher CJ Jr, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000;28 (9 Suppl): S49–S56.
- Angus DC, Vincent JL, Artigas A, Clermont G, Linde-Zwirble WT, Shanies HM, Kujath P, Henderson S, Kalil AC, Basson BC, Eli Lilly, Bernard GR. The effect of recombinant human activated protein C (rhAPC) on organ dysfunction and functional recovery in severe sepsis. Crit Care Med 2000; 28 (12S): 69A.
- Bernard GR, Hartman DL, Helterbrand JD, Fisher CJ. Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients with severe sepsis. Crit Care Med 1999;27 (1S): 33A.
- LaRosa SP, Vincent JL, Rinaldo B, Russell JA, Laterre PF, Artigas A, VanDerLinden CJ, Dhainaut JF, Riess H, Brown JM, Knobel E, Bernard GR. Baseline characteristics of patients enrolled in the phase III trial of rhAPC in severe sepsis. Crit Care Med 2000;28 (12S): 70A.
- Bernard GR, LaRosa SP, Laterre PF, Ely EW, Dhainaut JF, Fisher CJ, Rodriguez A, Helterbrand J, Stiengrub J, Carber G, Vincent JL. The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis. Crit Care Med 2000;28 (12S): 67A.
- Kinasewitz GT, Margolis B, Freebairn RC, Russell JA, Utterback BC, Basson B, Um SL, Bates BM, Eli Lilly, Opal S. Changes in markers of coagulation and inflammation in patients with severe sepsis treated with recombinant human activated protein C. Crit Care Med 2000;28 (12S): 68A.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 15, 2002 - Issue 2